Xilio Therapeutics

A2 Biotherapeutics

This company develops logic-gated T-cell therapies to treat patients with solid tumours by selectively targeting cancer cells while sparing healthy tissue.

Bicara Therapeutics

This biotechnology company develops dual-action biologics to treat patients with solid tumours by targeting the tumour microenvironment.

Daylight Biotherapeutics

This company develops T-cell engaging therapies for cancer patients to eliminate tumours while reducing systemic immune toxicity.

Theolytics

The company develops oncolytic viral immunotherapies for patients with solid tumours.

Waypoint Bio

This company develops cell therapies for solid tumours using a spatial biology and machine learning platform to assist patients with difficult-to-treat cancers.

Actym Therapeutics

This biotechnology company develops bacterial immunotherapies to treat solid tumours and fibrotic diseases for patients with advanced cancers.

Avenzo Therapeutics

This biotechnology company develops oncology therapies targeting solid tumours and metastatic breast cancer for patients with high unmet medical needs.

Avenge Bio

This biotechnology firm develops cell-based immunotherapies for patients with solid tumours, specifically targeting metastatic peritoneal cancers like ovarian cancer.